An experimental drug could help to improve movement for patients with spinal cord injuries.

NVG-291, an injectable peptide, has been tested in a phase 2 trial with eligible patients — some of whom noted remarkable outcomes.

Larry Williams, a trial participant based in Philadelphia, Pennsylvania, shared with Fox News Digital that he’s been able to walk again after an accident that caused paralysis.

Williams, 58, was mountain-biking on a small trail when he struck a tree. Although he was wearing a helmet, he “instantly broke” his C4 to C6 vertebrate (specific bones in the cervical spine).

He underwent spinal surgery, but was paralyzed for two weeks until his body began to “wake up” and regained some movement after starting therapy.

Williams was able to walk “a little bit” with th

See Full Page